Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Expansion of SAR studies on triaryl bis sulfone cannabinoid CB2 receptor ligands.

Tong L, Shankar BB, Chen L, Rizvi R, Kelly J, Gilbert E, Huang C, Yang DY, Kozlowski JA, Shih NY, Gonsiorek W, Hipkin RW, Malikzay A, Lunn CA, Lundell DJ.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6785-9. doi: 10.1016/j.bmcl.2010.08.126. Epub 2010 Aug 31.

PMID:
20850969
2.

Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.

Gilbert EJ, Zhou G, Wong MK, Tong L, Shankar BB, Huang C, Kelly J, Lavey BJ, McCombie SW, Chen L, Rizvi R, Dong Y, Shu Y, Kozlowski JA, Shih NY, Hipkin RW, Gonsiorek W, Malikzay A, Lunn CA, Favreau L, Lundell DJ.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):608-11. doi: 10.1016/j.bmcl.2009.11.084. Epub 2009 Nov 22.

PMID:
20005710
3.

Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.

Aki C, Chao J, Ferreira JA, Dwyer MP, Yu Y, Chao J, Merritt RJ, Lai G, Wu M, Hipkin RW, Fan X, Gonsiorek W, Fosseta J, Rindgen D, Fine J, Lundell D, Taveras AG, Biju P.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4446-9. doi: 10.1016/j.bmcl.2009.05.049. Epub 2009 May 18.

PMID:
19525110
4.

3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.

Biju P, Taveras AG, Yu Y, Zheng J, Hipkin RW, Fossetta J, Fan X, Fine J, Lundell D.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1434-7. doi: 10.1016/j.bmcl.2009.01.027. Epub 2009 Jan 15.

PMID:
19200721
5.

Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.

Biju P, Taveras AG, Dwyer MP, Yu Y, Chao J, Hipkin RW, Fan X, Rindgen D, Fine J, Lundell D.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1431-3. doi: 10.1016/j.bmcl.2009.01.033. Epub 2009 Jan 15.

PMID:
19196511
6.

CXCR2 antagonists for the treatment of pulmonary disease.

Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS.

Pharmacol Ther. 2009 Jan;121(1):55-68. doi: 10.1016/j.pharmthera.2008.10.005. Epub 2008 Oct 31. Review.

PMID:
19026683
7.

Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.

Yu Y, Dwyer MP, Chao J, Aki C, Chao J, Purakkattle B, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Qiu H, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, He Z, Lai G, Wu M, Taveras A.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1318-22. doi: 10.1016/j.bmcl.2008.01.024. Epub 2008 Jan 11.

PMID:
18242983
8.

Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss.

Lunn CA, Fine J, Rojas-Triana A, Jackson JV, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L.

Immunopharmacol Immunotoxicol. 2007;29(3-4):387-401.

PMID:
18075852
9.

3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.

Biju P, Taveras A, Yu Y, Zheng J, Chao J, Rindgen D, Jakway J, Hipkin RW, Fossetta J, Fan X, Fine J, Qiu H, Merritt JR, Baldwin JJ.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):228-31. Epub 2007 Oct 30.

PMID:
18006311
10.

Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.

Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L.

Br J Pharmacol. 2008 Jan;153(2):226-39. Epub 2007 Oct 1. Review.

11.

Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates.

Gonsiorek W, Lunn CA, Fan X, Deno G, Kozlowski J, Hipkin RW.

Br J Pharmacol. 2007 Aug;151(8):1262-71. Epub 2007 Jul 2.

12.

Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.

Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.

J Pharmacol Exp Ther. 2007 Aug;322(2):477-85. Epub 2007 May 11.

PMID:
17496166
13.

A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.

Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA.

J Pharmacol Exp Ther. 2007 Aug;322(2):486-93. Epub 2007 May 11.

PMID:
17496165
14.

Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8.

Fan X, Patera AC, Pong-Kennedy A, Deno G, Gonsiorek W, Manfra DJ, Vassileva G, Zeng M, Jackson C, Sullivan L, Sharif-Rodriguez W, Opdenakker G, Van Damme J, Hedrick JA, Lundell D, Lira SA, Hipkin RW.

J Biol Chem. 2007 Apr 20;282(16):11658-66. Epub 2006 Dec 29.

15.

Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.

Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, Girijavallabhan V, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, Rokosz LL, Kaiser B, Li G, Wang W, Stauffer T, Ozgur L, Baldwin J, Taveras AG.

J Med Chem. 2006 Dec 28;49(26):7603-6.

PMID:
17181143
16.

Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336.

Gonsiorek W, Hesk D, Chen SC, Kinsley D, Fine JS, Jackson JV, Bober LA, Deno G, Bian H, Fossetta J, Lunn CA, Kozlowski JA, Lavey B, Piwinski J, Narula SK, Lundell DJ, Hipkin RW.

J Biol Chem. 2006 Sep 22;281(38):28143-51. Epub 2006 Jun 5.

17.

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.

Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM.

Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9.

18.

A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.

Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA.

J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. Epub 2005 Oct 28.

PMID:
16258021
19.

Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies.

Shankar BB, Lavey BJ, Zhou G, Spitler JA, Tong L, Rizvi R, Yang DY, Wolin R, Kozlowski JA, Shih NY, Wu J, Hipkin RW, Gonsiorek W, Lunn CA.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4417-20.

PMID:
16115769
20.

Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.

Lavey BJ, Kozlowski JA, Hipkin RW, Gonsiorek W, Lundell DJ, Piwinski JJ, Narula S, Lunn CA.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):783-6.

PMID:
15664857
21.

Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.

Fossetta J, Deno G, Gonsiorek W, Fan X, Lavey B, Das P, Lunn C, Zavodny PJ, Lundell D, Hipkin RW.

Br J Pharmacol. 2004 Jul;142(5):851-60. Epub 2004 Jun 14.

22.

Cloning and pharmacological characterization of CXCR1 and CXCR2 from Macaca fascicularis.

Hipkin RW, Deno G, Fine J, Sun Y, Wilburn B, Fan X, Gonsiorek W, Wiekowski MT.

J Pharmacol Exp Ther. 2004 Jul;310(1):291-300. Epub 2004 Mar 17.

PMID:
15028780
23.
24.

Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68.

Jensen KK, Chen SC, Hipkin RW, Wiekowski MT, Schwarz MA, Chou CC, Simas JP, Alcami A, Lira SA.

J Virol. 2003 Jan;77(1):624-30.

25.

Homologous and heterologous regulation of somatostatin receptor 2.

Elberg G, Hipkin RW, Schonbrunn A.

Mol Endocrinol. 2002 Nov;16(11):2502-14.

PMID:
12403839
26.

Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.

Chou CC, Fine JS, Pugliese-Sivo C, Gonsiorek W, Davies L, Deno G, Petro M, Schwarz M, Zavodny PJ, Hipkin RW.

Br J Pharmacol. 2002 Nov;137(5):663-75.

27.

Evaluation of signal transduction pathways in chemoattractant-induced human monocyte chemotaxis.

Fine JS, Byrnes HD, Zavodny PJ, Hipkin RW.

Inflammation. 2001 Apr;25(2):61-7.

PMID:
11321360
28.
29.

Cloning and characterization of a novel human histamine receptor.

Morse KL, Behan J, Laz TM, West RE Jr, Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, Shin N, Gustafson EL, Qiao X, Wang S, Hedrick JA, Greene J, Bayne M, Monsma FJ Jr.

J Pharmacol Exp Ther. 2001 Mar;296(3):1058-66.

PMID:
11181941
30.

Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.

Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW.

Mol Pharmacol. 2000 May;57(5):1045-50.

PMID:
10779390
31.
32.

Pituitary somatostatin receptor (sst)1-5 expression during rat development: age-dependent expression of sst2.

Reed DK, Korytko AI, Hipkin RW, Wehrenberg WB, Schonbrunn A, Cuttler L.

Endocrinology. 1999 Oct;140(10):4739-44.

PMID:
10499533
33.
34.

Immunohistochemical localization of somatostatin receptors sst2A in human tumors.

Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A.

Am J Pathol. 1998 Jul;153(1):233-45.

35.

Desensitization of beta2-adrenergic receptors with mutations of the proposed G protein-coupled receptor kinase phosphorylation sites.

Seibold A, January BG, Friedman J, Hipkin RW, Clark RB.

J Biol Chem. 1998 Mar 27;273(13):7637-42.

36.
37.

beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists.

January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, Barber R, Clark RB.

J Biol Chem. 1997 Sep 19;272(38):23871-9.

38.

Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas.

Hunyady B, Hipkin RW, Schonbrunn A, Mezey E.

Endocrinology. 1997 Jul;138(7):2632-5.

PMID:
9202253
39.

Immunohistochemical Localization of Somatostatin Receptor SST2A in the Rat Pancreas.

Hunyady B, Hipkin RW, Schonbrunn A, Mezey EV.

Endocrinology. 1997 Jun 1;138(6):2632-2635. doi: 10.1210/endo.138.6.9105. No abstract available.

PMID:
28199610
40.

Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas.

Hunyady B, Hipkin RW, Schonbrunn A, Mezey E.

Endocrinology. 1997 Jun;138(6):2632-5. Corrected and republished in: Endocrinology. 1997 Jul;138(7):2632-5.

PMID:
9165058
41.

Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor.

Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A.

J Biol Chem. 1997 May 23;272(21):13869-76.

45.

Follitropin (FSH) and a phorbol ester stimulate the phosphorylation of the FSH receptor in intact cells.

Quintana J, Hipkin RW, Sánchez-Yagüe J, Ascoli M.

J Biol Chem. 1994 Mar 25;269(12):8772-9.

47.
50.

Interaction between cyclic nucleotide second messenger systems in murine Leydig cells.

Hipkin RW, Moger WH.

Mol Cell Endocrinol. 1991 Dec;82(2-3):251-7.

PMID:
1665454

Supplemental Content

Loading ...
Support Center